Clarametyx’s novel therapy aims to disrupt bacterial biofilms, one of the primary causes of antibiotic resistance, thereby potentially increasing the effectiveness of existing treatments in fighting a wide range of bacterial infections, including those commonly affecting people with CF.
Site Search
Showing 11 - 14 of 14 results
News
|
Jan. 5, 2024
|
2 min read
The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.
News
|
March 7, 2024
|
2 min read
Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.
News
|
March 18, 2024
|
2 min read
Since 2011, the Foundation has awarded $2.5 million across 35 different projects to improve cystic fibrosis newborn screening across the country.
News
|
Sept. 28, 2023
|
4 min read